生命科学资讯

Palvella unwraps Phase 2 data for rapamycin gel in rare skin disease

Sanofi MS drug hits two setbacks

Sanofi's tolebrutinib woes pile up with FDA delay, trial miss

Lumexa Imaging tallies $462.5M in IPO, doubling original target

Philips claims AI coronary imaging developer SpectraWAVE

Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout

Areteia Therapeutics to wind down after terminating Phase 3 asthma studies

Immunome's rare tumor drug passes Phase 3 test, could challenge Merck KGaA

Thermo Fisher Expands Gibco Bacto CD Portfolio with New E. coli Media - Contract Pharma

Biggest gainers and losers for Dec. 8-12, 2025

Twists, tangles, and transcription: Does epigenetics play a role in Alzheimer's? - Illumina

Agilent Technologies (NYSE:A) Upgraded at Barclays - MarketBeat

Agilent Technologies (A) Receives Analyst Rating Upgrade by Barc - GuruFocus

Agilent Technologies (A) Receives Analyst Rating Upgrade by Barc - GuruFocus

Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfront

Wells Fargo Adjusts PT on Thermo Fisher Scientific to $675 From $635, Maintains Overweight Rating - marketscreener.com

BofA Securities Maintains 10x Genomics(TXG.US) With Hold Rating, Announces Target Price $18 - 富途牛牛

USPPAR is a cost-effective, scalable, and highly sensitive single-cell RNA sequencing workflow compatible with diverse specimens

Bacterial gene 5′ ends have unusual mutation rates that can mislead tests of selection

Neville Rodie & Shaw Inc. Cuts Position in Thermo Fisher Scientific Inc. $TMO - MarketBeat